Julie Rachline ( )
Julie joigned Inspirit Partners in 2016 focusing on life sciences, medical devices, pharmaceutical and biotechnological industries. Julie brings her entrepreneurial experience, together with venture/growth capital and human resources skills.
In 2015, Julie founded LallianSe, which creates and manages part-time C-X-O’s for life sciences companies (www.lallianse.com
), and thus operates a global ecosystem to accelerate innovation and healthcare products.
Before, Julie served at Turenne Capital as an Investment Director, with an emphasis on life sciences and healthcare companies (venture/growth capital, LBO) where she invested in Stimulus Conseil, HalioDx or BrainEver. Besides, she was also Board Member of Voluntis, representing Sham Innovation Santé.
Prior to Turenne, Julie was Principal at L3S Partnership, an executive search boutique specialized in healthcare where she recruited senior management and top executives for global pharmaceutical companies, SMEs, start-up or public agencies.
At Matignon Investissement, from 2006 to 2011, she was involved with Nanobiotix (NANO), Ipsogen (ALIPS, then Qiagen), Eurogentec or FHOrthopedics and was already focusing on both venture/growth capital.
With a PhD in Neuropharmacology from École Normale Supérieure she holds from ESCP-Europe a master in marketing for the pharmaceutical industry. She studied in the USA at Roderick MacKinnon lab (Rockefeller University; Nobel Prize winner in 2003 [Chemistry]) and Spyros Artavanis-Tsakonas’ lab (Yale University).
Since 2013, Julie is coordinator at the Fondation pour l'Innovation Thérapeutique Béatrice Denys, which supports through grants up to € 50 000 French academic medical research leading to new ventures, under the auspices of the Fondation pour la Recherche Médicale.